Entrada Therapeutics
50 Northern Avenue
Boston
Massachusetts
02210
United States
Website: https://www.entradatx.com/
Email: info@entradatx.com
9 articles with Entrada Therapeutics
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Entrada Therapeutics Appoints Biotech Industry Leader Mary Thistle to Its Board of Directors
5/4/2021
Entrada Therapeutics, Inc., a biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointment of Mary Thistle to its Board of Directors.
-
April springs up with showers of cash for these life sciences companies.
-
Entrada Therapeutics Announces Closing of $116 Million Series B Financing
3/31/2021
Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the successful completion of a $116 million Series B financing.
-
BioSpace Movers & Shakers, Jan. 8
1/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, Dec. 11
12/11/2020
Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Entrada Therapeutics Strengthens Leadership Team with Key Appointments
12/8/2020
Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointments of Nerissa Kreher, M.D., as Chief Medical Officer and Kory Wentworth as Chief Financial Officer. Dr. Kreher, a physician executive with a 15-year record o
-
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
1/8/2020
Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.